| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2007, p. 8683-8697, Vol. 27, No. 24
0270-7306/07/$08.00+0 doi:10.1128/MCB.00157-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
,
Department of Cell and Developmental Biology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina,1 Department of Integrative Biology and Pharmacology, University of Texas Health Science Center at Houston, Houston, Texas2
Received 26 January 2007/ Returned for modification 5 March 2007/ Accepted 1 October 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Like all GTPases, Rho proteins act as molecular switches by cycling between an active (GTP-bound) and an inactive (GDP-bound) state. Active GTPases interact with high affinity with one of several downstream effectors to modulate their activity and localization. The activation of Rho GTPases is regulated by specific guanine nucleotide exchange factors (GEFs), which catalyze the exchange of GDP for GTP. Signaling is terminated when GTP is hydrolyzed to GDP, a process stimulated by GTPase-activating proteins. In addition, a third family of proteins, the guanine nucleotide dissociation inhibitors, negatively regulate Rho GTPases by sequestering them in the cytoplasm and interfering with both the GDP/GTP exchange and the GTP hydrolysis (65).
More than 70 Rho GEFs and 70 Rho GTPase-activating proteins are encoded by the human genome, allowing for pathway-specific regulation of Rho protein activity (51, 62). In addition, Rho GTPases interact with a wide variety of effectors and act as key players at the crossroads of signal integration and transduction (7, 24, 65).
Rho GEFs comprise a highly diverse family of proteins that share a common catalytic domain (Dbl homology [DH]), followed by a Pleckstrin homology (PH) domain, but are very different otherwise in their domain structures (51, 54). A striking feature of Rho GEFs is that they outnumber their target GTPases by a factor of 3, which means that multiple GEFs are capable of activating the same GTPase. In addition, many GEFs can activate more than one GTPase (51, 54). One of the fundamental questions in the field is how a cell utilizes specific combinations of GEF, GTPase, and effector to elicit defined responses to specific extracellular stimuli.
We have recently shown that 26 out of 70 Rho GEFs of the human DH family (37%) contain a putative PDZ-binding motif at the C terminus (18). These binding motifs are present in almost all of the corresponding mouse homologs, suggesting an evolutionarily conserved role. PDZ domains are protein-protein interaction domains that act as scaffolds to concentrate signaling molecules at specialized regions in the cell. In recent years, a series of PDZ proteins have been found to interact with Rho GEFs (18). These interactions result in targeting of the Rho GEFs to specific locations within the cell, in the restriction of the nucleotide exchange activity of Rho GEFs and also affect the spatial and temporal activation of the downstream GTPases (5, 11, 12, 37, 46, 47, 50).
Neuroepithelioma transforming gene 1 (Net1) is a RhoA-specific GEF that was originally identified in a genetic screen for novel oncogenes (8). The NET1 gene encodes a 595-amino-acid protein that consists of an N-terminal domain containing a series of nuclear localization signals (NLS), a DH-PH domain, and a short C-terminal domain carrying a consensus PDZ-binding motif (Fig. 1A). At steady state, Net1 localizes to the nucleus through the function of its NLS (55). Deletion of the N-terminal domain containing the NLS sequences redistributes Net1 to the cytosol and promotes the formation of actin stress fibers, which is a consequence of RhoA activation (2, 55). The oncogenic Net1 clone isolated in the original screen encoded a truncated protein in which the first 145 amino acids, including the NLS, were missing, suggesting that relocalization of the RhoA exchange activity to the cytosol was responsible for the transformation ability of Net1 (8, 55). However, further studies demonstrated that a high exchange activity in the cytosol was not sufficient to induce transformation (49). In addition, these studies demonstrated that the PDZ-binding motif was essential for Net1-mediated transformation of NIH 3T3 cells, suggesting that the interaction between Net1 and a PDZ domain protein could be playing a role.
|
| MATERIALS AND METHODS |
|---|
|
|
|---|
4 mutations (Net
4 and Net
N
4) were made by introducing a stop codon before the PDZ-binding motif, using a QuikChange II mutagenesis kit (Stratagene). V
A and L267E substitutions were also made using a QuikChange II mutagenesis kit. All constructs were verified by DNA sequencing. Cell culture and transfection. HeLa cells were cultured in modified Eagle's medium (Invitrogen) supplemented with nonessential amino acids, 10% fetal bovine serum (FBS) (Sigma), and antibiotics (penicillin-streptomycin). HEK293 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Invitrogen) supplemented with nonessential amino acids, 10% FBS, and antibiotics. NIH 3T3 cells were cultured in DMEM supplemented with 10% bovine calf serum and antibiotics (Sigma). MCF10a cells were cultured in DMEM-F12 (Invitrogen) supplemented with 5% horse serum (Invitrogen), 20 ng/ml epidermal growth factor (Sigma), 0.01 mg/ml insulin (Invitrogen), 500 ng/ml hydrocortisone (Invitrogen), and antibiotics. MCF7 cells were grown in minimal essential medium (Invitrogen) supplemented with FBS, Na pyruvate (Invitrogen), and antibiotics. Cells were transfected using FuGene6 or FuGene HD (Roche) according to the manufacturer's instructions.
Small interfering RNA (siRNA) against human Net1 was from Dharmacon Research. The RNA sequences were as follows: sense, 5'-GAGUCUCCCUUCAGUCGAAUU-3', and antisense, 5'-UUCGACUGAAGGGAGACUCUU-3'. As a control, we used siGLO RISC-Free nontargeting siRNA (Dharmacon). HEK293 cells were transfected using the TransIT siQuest transfection reagent (Mirus), following the manufacturer's instructions. Cells were assayed 96 h after transfection.
Peptide pulldowns. Tissues were homogenized in a Dounce homogenizer in 5 volumes of buffer HNMD (HEPES-KOH, 50 mM [pH 7.4]; NaCl, 150 mM; MgCl2, 1 mM; dithiothreitol [DTT], 1 mM; and freshly added protease inhibitors and 1% Triton X-100). The homogenates were then centrifuged for 15 min at 27,000 x g. The supernatants (10 mg/experiment at 1 mg/ml) were then precleared for 1 h at 4°C using streptavidin-Sepharose beads (100 µl) (GE). At the same time, 40 µg of peptide was incubated with 40 µl of streptavidin beads in HNMD for 1 h at 4°C. The beads were then washed three times with HNMD and incubated with 10 mg of precleared lysate for 1 h at 4°C on a rotating platform. The beads were then washed three times in binding buffer, resuspended in 30 µl of sodium dodecyl sulfate (SDS) sample buffer, boiled for 10 min, and separated by SDS-polyacrylamide gel electrophoresis (PAGE). The bands of interest were then identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MS), and selected tryptic peptides were sequenced by Nano-ESI tandem MS at the UNC proteomics facility.
GST pulldowns and immunoprecipitation. Cells were washed twice in phosphate-buffered saline (PBS), lysed in lysis buffer (HEPES-KOH, 50 mM [pH 7.4]; NaCl, 150 mM; MgCl2, 1 mM; DTT, 1 mM; and freshly added protease inhibitors and 1% Triton X-100) and centrifuged at 16,000 x g for 15 min at 4°C. Tissue lysates were prepared as described above. Glutathione S-transferase (GST)-tagged proteins bound to glutathione-Sepharose (GE) were incubated with lysates for 1 h at 4°C. The beads were then washed three times in lysis buffer, resuspended in 30 µl of SDS sample buffer, boiled for 10 min, and separated by SDS-PAGE. Proteins were then transferred to nitrocellulose and immunoblotted with the indicated antibodies. For immunoprecipitation, cell lysates were incubated with antibodies (2 µg) and incubated for 1 h at 4°C. Protein G-Sepharose (GE) was then added and incubated for 45 min at 4°C. Immune complexes were recovered by centrifugation, washed three times with lysis buffer, and boiled in SDS sample buffer. After SDS-PAGE, proteins were transferred to nitrocellulose and immunoblotted with the indicated antibodies.
RhoA activity pulldowns. Construction of the pGEX4T-1 prokaryotic expression constructs containing the Rho binding domain (RBD) of rhotekin have been described previously (36). Briefly, expression of the fusion proteins in Escherichia coli was induced with 100 µM IPTG (isopropyl-ß-D-thiogalactopyranoside) for 12 to 16 h at room temperature. Bacterial cells were lysed in buffer containing 50 mM Tris (pH 7.6), 150 mM NaCl, 5 mM MgCl2, 1 mM DTT, 10 µg/ml each of aprotinin and leupeptin, and 1 mM phenylmethylsulfonyl fluoride (PMSF) and the proteins purified by incubation with glutathione-Sepharose 4B beads (GE) at 4°C. Active RhoA pulldown experiments were performed as described elsewhere (3). Briefly, suspended and adherent cells were lysed in 50 mM Tris (pH 7.6), 500 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate, 10 mM MgCl2, 200 µM orthovanadate, and protease inhibitors. Lysates were clarified by centrifugation, equalized for total volume and protein concentration, and rotated for 30 min with 30 µg of purified GST-RBD bound to glutathione-Sepharose beads. The bead pellets were washed in 50 mM Tris (pH 7.6), 150 mM NaCl, 1% Triton X-100, 10 mM MgCl2, 200 µM orthovanadate, and protease inhibitors and subsequently processed for SDS-PAGE.
Subcellular fractionation.
Intact nuclei were isolated using an iodixanol (OptiPrep; Axis Shield) discontinuous gradient according to the manufacturer's instructions. Briefly, cells were rinsed three times with PBS and scraped in homogenization medium (0.25 M sucrose, 25 mM KCl, 5 mM MgCl2, 20 mM Tris-HCl, pH 7.8, 10 µg/ml each of aprotinin and leupeptin, and 1 mM PMSF). Cells were then centrifuged for 10 min at 1,000 x g, and the pellet was resuspended in homogenization medium. The cell suspension was homogenized using 20 strokes of the pestle of a tight-fitting Dounce homogenizer. Homogenization was monitored under a phase-contrast microscope until >90% of the cells were broken. The homogenate was then centrifuged to produce a crude nuclear pellet (1,000 x g for 10 min) and resuspended in homogenization medium. Equal volumes of the crude nuclear pellet and a 50% iodixanol solution were then mixed and layered on top of a 30% to 35% discontinuous iodixanol gradient. The samples were then centrifuged at 10,000 x g for 20 min in a swinging bucket rotor. The nuclear fraction (30 to 35% interface) was collected, diluted with 2 volumes of homogenization medium, and centrifuged for 10 min at 1,000 x g. The pellet fraction, which contains nuclei, was resuspended in 100 µl of ice-cold nuclear extraction buffer (20 mM HEPES, pH 7.9, with 1.5 mM MgCl2, 0.42 M NaCl, 0.2 mM EDTA, 25% [vol/vol] glycerol, 10 µg/ml each of aprotinin and leupeptin, and 1 mM PMSF) and vortexed at the highest setting for 15 seconds every 10 min for a total of 40 min of extraction. The samples were then briefly sonicated and centrifuged at maximum speed (
16,000 x g) in a microcentrifuge for 10 min, and the supernatant (nuclear extract) fraction was transferred to a clean, prechilled tube. Samples were stored at –80°C until use.
Immunofluorescence microscopy. Cells grown on coverslips were washed in PBS, fixed in 3.7% paraformaldehyde for 10 min, and quenched with 10 mM ammonium chloride in PBS. Cells were permeabilized with 0.1% Triton X-100 in PBS for 10 min. The coverslips were then washed with PBS and blocked in PBS plus 2.5% goat serum and 0.2% Tween 20 for 5 min, followed by blocking in PBS plus 0.4% fish skin gelatin and 0.2% Tween 20. Cells were incubated with primary antibody for 1 h at room temperature. Coverslips were washed five times for 5 min with PBS plus 0.2% Tween 20 and incubated with secondary antibodies for 45 min. Coverslips were washed as described above and mounted on slides in 9:1 glycerol-PBS with 0.1% p-phenylenediamine. Epifluorescence images were captured with a Zeiss Axiovert 200 M microscope equipped with a Hamamatsu ORCA-ERAG digital camera and Metamorph Workstation (Universal Imaging Corp.). Quantitative analysis was performed using Metamorph to measure the average fluorescence intensity per cell in images that were serially acquired using the same illumination and exposure parameters. Confocal image acquisition and analysis were performed using a Leica SP2 AOBS confocal microscope with a 63x, 1.4-numerical-aperture apochromatic Leica lens (Leica Microsystems). Scanning was performed with the xy axis, using three independent laser sources (364-nm-UV, 488-nm-Ar, 568-nm-Kr lasers), as required. Images were processed using Leica and Adobe Photoshop software.
Focus formation assays. Primary focus formation assays were performed with NIH 3T3 cells as described previously (58). Briefly, NIH 3T3 cells were transfected using the Amaxa nucleofection system (6 to 8 µg of DNA/1 x 106 to 2 x 106 cells) and plated into three 6-cm-diameter dishes. Twenty-four hours after transfection, the bovine calf serum concentration was reduced from 10% to 5%. Medium was changed every 2.5 days. Cells were fixed 12 to 14 days later and stained with a solution containing 30% methanol and 0.4% crystal violet. Foci larger than 1 mm in diameter were scored.
Electron microscopy. HeLa cells were plated on coverslips and grown for 24 h. Cells were then transfected and chemically fixed in 2.5% glutaraldehyde and 1% tannic acid in 0.1 M cacodylate buffer (pH 7.3) for 1 h at 4°C. Following fixation, cells were washed with 0.1 M cacodylate buffer, treated for 1 h with cold 0.5% osmium tetroxide, washed with water and once with 50% ethanol, stained with 2% uranyl acetate in the dark for 30 min, and dehydrated through a graded ethanol series. Sections were infiltrated and embedded in an epoxy resin (EMbed-812; Electron Microscopy Sciences). Vibratome sections were bisected along the equatorial and optic axes and mounted for ultramicrotome sectioning. Mesas were raised in the regions of interest, and 55-nm thin sections were cut with a diamond knife (Diatome). The sections were collected on copper grids and stained with uranyl acetate and lead citrate. The specimens were examined using an FEI Philips Tecnai 12 TEM electron microscope (FEI Company) at 80 kV. Images were captured using a Gatan 794 digital camera (Gatan Inc.) and Digital Micrograph software (Gatan Inc.).
| RESULTS |
|---|
|
|
|---|
4-GST) or a single-amino-acid-substitution mutant in which the C-terminal amino acid valine was replaced by an alanine (Net1V
A-GST). In agreement with the results from the peptide pulldowns, only the full-length Net1 protein was able to interact with PSD95, Dlg1, and SAP102, not the
4 mutant or the V
A mutant, suggesting that these interactions were specifically mediated by the PDZ-binding motif at the C terminus of Net1 (Fig. 1E and F). This interaction is direct and requires PDZ domains 1 and 2 from Dlg1 (H. S. Carr and J. A. Frost, personal communication). To confirm that the interaction also occurred with endogenous proteins, we immunoprecipitated Dlg1 from HEK293 lysates and blotted for Net1. As shown in Fig. 1G, Net1 coimmunoprecipitated with Dlg1 antibodies but not with control antibodies. In addition, we were able to coimmunoprecipitate endogenous Dlg1 and Net1 from purified nuclei (see Fig. S3B in the supplemental material). The reverse coimmunoprecipitation could not be performed successfully, because the Net1 antibodies available were raised against a peptide corresponding to the Net1 C terminus, which includes the PDZ-binding tail, a region that is probably masked when the two proteins interact. Interaction with Net1 causes the relocalization of Dlg proteins from the cytosol to defined nuclear subdomains. In many cases, the interaction of a protein with a PDZ domain-containing protein plays a role in targeting the protein to a specific cellular localization. In particular, PDZ scaffolding proteins such as PSD95, Dlg1, and SAP102 have been shown to concentrate or cluster neurotransmitter receptors at the plasma membrane in the postsynaptic dendritic spines (13, 27, 56). This same effect was observed when the two interaction partners were transfected in a heterologous cell system (31, 32). Since Net1 shuttles between the nucleus and the cytosol, we hypothesized that its interaction with a PDZ protein in the cytosol may play a role in targeting and/or sequestering Net1 in the cytosol, where it can activate RhoA and perform its cellular function. To test this hypothesis, we cotransfected full-length, myc epitope-tagged Net1 with PSD95, SAP102, or Dlg1 into HeLa cells. Each PDZ protein was fused to GFP to allow for visualization of its localization. Our results show that, as previously reported, Net1 localized to the nucleus and to some extent to the cytosol when singly transfected (Fig. 2A) (1, 49, 55).
|
|
4). We have shown in Fig. 1 that the equivalent mutation in a NET-GST fusion protein blocked binding to PSD95, Dlg1, and SAP102 in pulldown experiments. We observed that the Net1
4 mutant behaved like the full-length Net1 protein when transfected alone, localizing predominantly to the nucleus and causing the formation of actin stress fibers when expressed at high levels (Fig. 3A). Importantly, when Net1
4 was coexpressed with PSD95, Dlg1, or SAP102, the relocalization of the PDZ proteins to the nucleus and the formation of nuclear clusters were completely abolished (Fig. 3B and E for quantification). Instead, each of these proteins showed a diffuse, cytosolic pattern that was indistinguishable from that observed when they were expressed alone (Fig. 2B). These results demonstrate that Net1 must interact with PDZ domain proteins through its PDZ-binding site to cause their nuclear relocalization. Formation of the nuclear clusters is independent of the exchange activity of Net1. We next wanted to examine the role of Net1 nucleotide exchange activity in the relocalization of the PDZ proteins and the formation of the nuclear clusters. To address this, we generated a single-amino-acid-substitution mutant which has been previously shown to inhibit the catalytic activity of Net1 (L321E in Net1, L267E in Net1A) (2). As expected, overexpression of the inactive Net1 protein in HeLa cells had no effect on stress fiber formation (Fig. 3C). Interestingly, cotransfection of Net1-L267E with PSD95, Dlg1, or SAP102 did not prevent the formation of nuclear clusters (Fig. 3D and F). Similarly, a mutation in the PH domain (Net1W492L) previously described as catalytically inactive (2) was as efficient as wild-type Net1 in its ability to recruit Dlg proteins to the nucleus and target them to nuclear clusters (data not shown). Taken together, these results demonstrate that the relocalization of PDZ proteins into the nucleus and the formation of nuclear clusters do not require Net1-mediated RhoA activation.
The interaction between Net1 and Dlg proteins has no effect in Net1-mediated RhoA activation.
As shown in Fig. 3, the formation of the nuclear clusters was not inhibited by abrogating the exchange activity in Net1. However, that did not eliminate the possibility that the interaction between Dlg proteins and Net1 had an effect on Net1 exchange activity on RhoA. To determine if this was the case, we transfected HeLa cells with Net1
N alone or in combination with two members of the Dlg family, Dlg1 and SAP102. We then analyzed their effect on RhoA activity by looking at the formation of stress fibers in transfected cells. As shown in Fig. 4, overexpression of Net1
N induces a striking increase in the formation of stress fibers. In contrast, neither Dlg1 nor SAP102 by itself had any effect on stress fiber formation. When Dlg1 or SAP102 was cotransfected with Net1
N, we could not detect any significant difference from cells singly transfected with Net1
N, suggesting that the interaction was not affecting Net1 exchange activity. Quantitation of F-actin fluorescence intensity supports our conclusion and shows that there is no significant difference between cells transfected with Net1
N and those cotransfected with Dlg protein (Fig. 4C). We also measured RhoA GTP levels in a similar set of transfected cells by using a pulldown assay. The results of the pulldown assay show essentially the same results as those observed in the immunofluorescence analysis, that is, Net1
N induces RhoA activation compared to what occurs in nontransfected, starved cells. This activity is not affected significantly by cotransfecting Dlg1 or SAP102 (Fig. 4D). Taken together, our results suggest that the interaction between Net1 and Dlg proteins does not seem to be involved in the regulation of Net1's exchange activity.
|
|
|
N) (Fig. 6A) and coexpressed it with PSD95, Dlg1, or SAP102 in HeLa cells. As previously described, while the
N mutant was still able to target to the nucleus to a small extent, the majority of the protein localized to the cytosol (Fig. 6B) (49, 55). Surprisingly, when Net1
N was coexpressed with the PDZ proteins, the PDZ protein clusters are still formed, but they were completely excluded from the nucleus and instead distributed evenly throughout the cytosol (Fig. 6C). The cytosolic clusters did not appear to contain Net1
N, as judged by the myc staining. However, when we repeated the experiment using an mCherry-labeled Net1
N mutant, we observed perfect colocalization, suggesting that the inability to see Net1
N in the cytosolic clusters was attributable to a lack of accessibility of the myc epitope (see Fig. S1 in the supplemental material). We also observed that the formation of these cytosolic clusters was abrogated by deleting the PDZ-binding site in Net1
N, indicating the requirement for interaction between Net1 and PDZ-binding proteins for cluster formation (shown for SAP102 cotransfection in Fig. 6D). These data also indicate that nuclear localization is not a requisite for these coclusters to form.
Endogenous Dlg1 localization is affected by overexpression of Net1 or by reduction of endogenous Net1 levels.
We also wanted to determine if overexpression of Net1 or Net1 mutants was able to affect the localization of endogenous Dlg1. We therefore transfected MCF10a cells, which express endogenous Dlg1, with different Net1 constructs and analyzed Dlg1 localization by immunofluorescence. Figure 7A shows that overexpression of full-length Net1 promoted the translocation of Dlg1 from cell junctions to the nucleus. In many cases, we found Dlg1 colocalizing with Net1 in nuclear subdomains similar to those observed in the cotransfection experiments. The relocation of Dlg1 was completely abolished when we overexpressed Net1
4, which is still targeted to the nucleus but is unable to bind Dlg1, suggesting that it is being mediated by the interaction between the PDZ domains in Dlg1 and the PDZ-binding tail in Net1 (Fig. 7B). XPLN, another RhoA GEF that also binds PDZ proteins, is unable to relocate Dlg1 upon overexpression, suggesting that the effect observed is specific for Net1 (Fig. 7C). In addition, Net1
N, which is mostly cytosolic, also promotes the relocation of endogenous Dlg1, this time from cell junctions to a diffuse cytosolic pattern. In some cells, we observed cytosolic clusters similar to the ones shown in Fig. 6 (Fig. 7D). It appears in some of the images in Fig. 7 that only the transfected cells are expressing Dlg1. There are two main reasons for this apparent anomaly. First, methanol fixation, which is required to visualize nuclear Dlg1, significantly decreases the Dlg1 signal at the membranes. Second, the signal of nuclear Dlg1 in transfected cells is highly concentrated in a small area, making it difficult for the camera to capture the weaker signal at the junctions. Overall, it appears that the junctional staining is reduced and nuclear staining (or cytosolic staining in the case of
N) is greatly increased in transfected cells, while in reality, Dlg1 relocates only upon transfection and the difference observed is caused by the reduction in junctional staining resulting from the methanol fixation (see Fig. S2 in the supplemental material). We also tested the stability of Dlg1 upon Net1 transfection to see if Net1 overexpression could confer stability to Dlg1 and cause its accumulation over time. We transfected cells with different amounts of Net1 or Net1
N and then blotted for Dlg1 to see if we could detect an increase in Dlg1 levels in transfected cells. Our results showed that Net1 or Net1
N failed to increase Dlg1 stability and, under at least one condition, even caused a slight decrease in Dlg1 levels. These results suggest that the stability of Dlg1 is not responsible for the apparent accumulation observed in transfected cells (see Fig. S2C and E in the supplemental material).
|
Role of Net1 interaction with PDZ proteins in transformation.
The observation that coexpression of the oncogenic Net1
N mutant with PDZ domain proteins caused the formation of clusters in the cytosol suggests that Net1
N may sequester these proteins from their natural partners/effectors and prevent them from performing their normal function. Interestingly, Dlg1/SAP97 has been shown to function as a tumor suppressor protein in Drosophila and in mammals (20, 45, 64, 69-71). In addition, a mutant of Net1
N lacking its PDZ-binding motif loses its transformation potential, suggesting that binding to a PDZ protein is required for transformation (49). We hypothesized that the transformation ability of Net1
N was dependent on its ability to bind and sequester Dlg1 (or other Dlg proteins) in the cytosol, away from its normal cellular location and/or binding partners. One prediction of this hypothesis is that if we restore the amount of Dlg1 by overexpressing it, there would be enough "active" or "free" Dlg1 that can act as a tumor suppressor and reduce Net1
N transformation potential. To test this prediction, we coexpressed wild-type and oncogenic Net1, alone or together with Dlg1 or SAP102, in NIH 3T3 cells and performed a focus formation assay. As previously described, wild-type Net1 was unable to induce transformation while expression of Net1
N induced a significant increase in the number of foci formed after 2 weeks (Fig. 8A and B) (2, 49). However, when either Dlg1 or SAP102 was coexpressed with Net1
N, a significant reduction in the number of colonies was observed. To rule out that the observed reduction was simply a result of overexpressing a tumor suppressor, SAP102 was coexpressed with another RhoA GEF, p115-RhoGEF, which upon deletion of its C terminus is also a potent oncogene (10, 16, 68). Oncogenic p115-RhoGEF (p115
C) does not contain a PDZ-binding site and has not been shown to interact with SAP102 (18). Our results show that coexpression of SAP102 with the oncogenic p115-RhoGEF had no effect on the number of foci formed after 2 weeks, suggesting that its effect on Net1
N-mediated transformation was specific (Fig. 8C and D).
|
| DISCUSSION |
|---|
|
|
|---|
Originally, it was thought that the ability of Net1 to transform cells was due to the fact that the
N mutant was constitutively active in the cytosol (55). However, it was later shown that wild-type Net1 artificially targeted to the cytosol is still active but cannot induce transformation (49). In addition, it was also shown that deletion of the last four amino acids in Net1, carrying a consensus PDZ-binding motif, abrogated its transformation properties but not its exchange activity, suggesting that binding to a PDZ protein was necessary for the process of transformation (49).
In this study, we identified several PDZ domain-containing proteins as potential binding partners for Net1 and specifically characterized the interaction of Net1 with three members of the Dlg family of proteins, PSD95, Dlg1/SAP97, and SAP102. We found that the binding of Net1 to these proteins promotes their relocation from the cytosol to discrete nuclear subdomains. This relocation requires the PDZ-binding domain and the NLS in Net1. In addition, we found that reducing Net1 levels using siRNA causes a redistribution of endogenous Dlg1 from the nucleus to the cytosol.
Although most PDZ proteins are associated with plasma membrane-bound proteins, there are several examples in the literature of PDZ proteins, including Dlg1, that are able to shuttle between the nucleus and the cytosol. For example, endogenous Dlg has been shown to localize to the nucleus in various cell types and tissues (39, 40). In this regard, Dlg1 is predicted to contain four or five putative NLS, but it is not clear which ones contribute to the nuclear localization (40). CASK, another member of the MAGUK family of proteins, has also been found to shuttle between the nucleus and the cytosol (29). CASK interacts with Tbr1, a transcription factor involved in mouse forebrain development. Once in the nucleus, CASK and Tbr-1 bind to a specific DNA sequence (the T element). In this context, CASK acts as a coactivator of Tbr-1 to induce the transcription of T-element-containing genes (29). Similarly, a splice variant of the PDZ protein NHERF2, named SIP-1, was identified as a nuclear factor binding to SRY, a Y-chromosome-specific gene that acts as a trigger for male sex development (48). SIP-1 is also proposed to function as a transcriptional coactivator (48, 63). Taken together, these studies suggest potential roles for some PDZ proteins in the nucleus, most likely associated with transcriptional regulation.
The interaction between Net1 and members of the Dlg family not only targets them to the nucleus but also localizes the complexes in discrete nuclear subdomains. The nucleus is organized into many functionally specialized subdomains that have been characterized as organelles (26, 59). Subnuclear organelles differ in size, shape, and molecular components, and the functions of most of these organelles are still unknown. Our work suggests that the structures formed by Net1 in complex with PDZ proteins are closely associated with PML bodies. PML bodies, also known as PML oncogenic domains or nuclear domain 10 (ND10), are defined by the presence of the PML protein. Approximately 10 to 30 bodies are observed in each cell, ranging from
0.2 to 1.0 µm each. PML bodies are multiprotein complexes that have been shown to contain at least 50 different proteins (41). Studies of the physiological role of PML bodies and the PML protein have shown that they play a role in transformation suppression, growth control, differentiation, and immune response pathways (6, 41). It would be interesting to determine if the ability of Dlg1 to localize to the nucleus in close association with PML bodies is correlated to its tumor suppressor function.
Dlg1 is the mammalian homolog of the Drosophila discs-large (Dlg) tumor suppressor protein (38, 43). Loss of zygotic Dlg in Drosophila causes cellular outgrowth in larval brain and imaginal discs (20, 70, 71). Transgenic expression of mammalian Dlg1 and SAP102 can suppress tumor formation in dlg mutant flies and mimic Dlg at larval neuromuscular junctions, demonstrating a conservation in the tumor suppressor function (64). Dlg1 has also been shown to prevent unscheduled growth in mouse retina (45). Our data suggest that oncogenic Net1 may promote transformation by promoting the translocation of Dlg1, PSD95, and SAP102 into cytosolic clusters. This may sequester Dlg1 away from its normal localization or compete for other binding partners to promote unrestricted growth and transformation. In a similar manner, several viral oncoproteins that contain PDZ-binding tails have been shown to interact with Dlg1 and other PDZ-containing proteins (33, 34, 52). It has also been shown that the PDZ-binding motif plays a role in transformation induced by these oncoproteins (28, 34, 66). Upon interacting with Dlg1, these viral proteins inactivate the tumor suppressor protein through different molecular mechanisms. For example, the high-risk human papillomavirus E6 protein targets human Dlg1 (hDlg) and PSD95 (Dlg4) for degradation (19, 25). Significantly, only E6 proteins that are derived from oncogenic human papillomavirus types can interact with hDlg, and E6 mutants that can no longer bind hDlg also lose their transforming activity (33). In addition, E6 has been shown to colocalize at the nucleus with PML bodies (22, 23). Similarly, the viral oncoprotein Tax1, which is from human T-cell leukemia virus 1, can also bind to Dlg1 and perturb its tumor suppression function, by a mechanism that does not involve degradation of Dlg1 (60). In contrast, the adenovirus type 9 E4-ORF1 oncoprotein induces transformation by binding to Dlg1 through a pathway that requires Src-dependent phosphatidylinositol 3-kinase activation (14). In this regard, we have not observed degradation of Dlg1 or the other PDZ proteins upon interaction with Net1, but it is possible that the cytosolic aggregation or clustering may also inhibit the tumor suppressor function of Dlg1 by preventing it from interacting with its physiological binding partners or from targeting to its appropriate cellular destination. Future experiments will be directed to characterize the molecular mechanisms by which the interaction between Net1 and PDZ proteins contributes to Net1-dependent transformation.
| ACKNOWLEDGMENTS |
|---|
We thank Hal Mekeel for his assistance with electron microscopy. We thank Klaus Hahn, Mike Ehlers, and Karl Fu for providing reagents.
| FOOTNOTES |
|---|
Published ahead of print on 15 October 2007. ![]()
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Alberts, A. S., and R. Treisman. 1998. Activation of RhoA and SAPK/JNK signalling pathways by the RhoA-specific exchange factor mNET1. EMBO J. 17:4075-4085.[CrossRef][Medline]
3. Arthur, W. T., and K. Burridge. 2001. RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol. Biol. Cell 12:2711-2720.
4. Arthur, W. T., S. M. Ellerbroek, C. J. Der, K. Burridge, and K. Wennerberg. 2002. XPLN, a guanine nucleotide exchange factor for RhoA and RhoB, but not RhoC. J. Biol. Chem. 277:42964-42972.
5. Audebert, S., C. Navarro, C. Nourry, S. Chasserot-Golaz, P. Lecine, Y. Bellaiche, J. L. Dupont, R. T. Premont, C. Sempere, J. M. Strub, A. Van Dorsselaer, N. Vitale, and J. P. Borg. 2004. Mammalian Scribble forms a tight complex with the betaPIX exchange factor. Curr. Biol. 14:987-995.[CrossRef][Medline]
6. Borden, K. L. 2002. Pondering the promyelocytic leukemia protein (PML) puzzle: possible functions for PML nuclear bodies. Mol. Cell. Biol. 22:5259-5269.
7. Burridge, K., and K. Wennerberg. 2004. Rho and Rac take center stage. Cell 116:167-179.[CrossRef][Medline]
8. Chan, A. M., S. Takai, K. Yamada, and T. Miki. 1996. Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning. Oncogene 12:1259-1266.[Medline]
9. Chen, T. L., P. Y. Wang, W. Luo, S. S. Gwon, N. W. Flay, J. Zheng, C. Guo, M. L. Tanzer, and B. M. Vertel. 2001. Aggrecan domains expected to traffic through the exocytic pathway are misdirected to the nucleus. Exp. Cell Res. 263:224-235.[CrossRef][Medline]
10. Chikumi, H., A. Barac, B. Behbahani, Y. Gao, H. Teramoto, Y. Zheng, and J. S. Gutkind. 2004. Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. Oncogene 23:233-240.[CrossRef][Medline]
11. Dobrosotskaya, I. Y. 2001. Identification of mNET1 as a candidate ligand for the first PDZ domain of MAGI-1. Biochem. Biophys. Res. Commun. 283:969-975.[CrossRef][Medline]
12. Fabre, S., C. Reynaud, and P. Jalinot. 2000. Identification of functional PDZ domain binding sites in several human proteins. Mol. Biol. Rep. 27:217-224.[CrossRef][Medline]
13. Fanning, A. S., and J. M. Anderson. 1996. Protein-protein interactions: PDZ domain networks. Curr. Biol. 6:1385-1388.[CrossRef][Medline]
14. Frese, K. K., I. J. Latorre, S. H. Chung, G. Caruana, A. Bernstein, S. N. Jones, L. A. Donehower, M. J. Justice, C. C. Garner, and R. T. Javier. 2006. Oncogenic function for the Dlg1 mammalian homolog of the Drosophila discs-large tumor suppressor. EMBO J. 25:1406-1417.[CrossRef][Medline]
15. Fu, L., Y. S. Gao, A. Tousson, A. Shah, T. L. Chen, B. M. Vertel, and E. Sztul. 2005. Nuclear aggresomes form by fusion of PML-associated aggregates. Mol. Biol. Cell 16:4905-4917.
16. Fukuhara, S., H. Chikumi, and J. S. Gutkind. 2001. RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho? Oncogene 20:1661-1668.[CrossRef][Medline]
17. Garcia-Mata, R., Z. Bebok, E. J. Sorscher, and E. S. Sztul. 1999. Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J. Cell Biol. 146:1239-1254.
18. Garcia-Mata, R., and K. Burridge. 2007. Catching a GEF by its tail. Trends Cell Biol. 17:36-43.[CrossRef][Medline]
19. Gardiol, D., C. Kuhne, B. Glaunsinger, S. S. Lee, R. Javier, and L. Banks. 1999. Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene 18:5487-5496.[CrossRef][Medline]
20. Goode, S., and N. Perrimon. 1997. Inhibition of patterned cell shape change and cell invasion by Discs large during Drosophila oogenesis. Genes Dev. 11:2532-2544.
21. Grande, M. A., I. van der Kraan, B. van Steensel, W. Schul, H. de The, H. T. van der Voort, L. de Jong, and R. van Driel. 1996. PML-containing nuclear bodies: their spatial distribution in relation to other nuclear components. J. Cell. Biochem. 63:280-291.[CrossRef][Medline]
22. Guccione, E., K. J. Lethbridge, N. Killick, K. N. Leppard, and L. Banks. 2004. HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures. Oncogene 23:4662-4672.[CrossRef][Medline]
23. Guccione, E., P. Massimi, A. Bernat, and L. Banks. 2002. Comparative analysis of the intracellular location of the high- and low-risk human papillomavirus oncoproteins. Virology 293:20-25.[CrossRef][Medline]
24. Hall, A. 2005. Rho GTPases and the control of cell behaviour. Biochem. Soc. Trans. 33:891-895.[CrossRef][Medline]
25. Handa, K., T. Yugawa, M. Narisawa-Saito, S. I. Ohno, M. Fujita, and T. Kiyono. 2007. E6AP-dependent degradation of DLG4/PSD95 by high-risk human papillomavirus type 18 E6 protein. J. Virol. 81:1379-1389.
26. Handwerger, K. E., and J. G. Gall. 2006. Subnuclear organelles: new insights into form and function. Trends Cell Biol. 16:19-26.[CrossRef][Medline]
27. Harris, B. Z., and W. A. Lim. 2001. Mechanism and role of PDZ domains in signaling complex assembly. J. Cell Sci. 114:3219-3231.[Medline]
28. Hirata, A., M. Higuchi, A. Niinuma, M. Ohashi, M. Fukushi, M. Oie, T. Akiyama, Y. Tanaka, F. Gejyo, and M. Fujii. 2004. PDZ domain-binding motif of human T-cell leukemia virus type 1 Tax oncoprotein augments the transforming activity in a rat fibroblast cell line. Virology 318:327-336.[CrossRef][Medline]
29. Hsueh, Y. P., T. F. Wang, F. C. Yang, and M. Sheng. 2000. Nuclear translocation and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2. Nature 404:298-302.[CrossRef][Medline]
30. Karnoub, A. E., M. Symons, S. L. Campbell, and C. J. Der. 2004. Molecular basis for Rho GTPase signaling specificity. Breast Cancer Res. Treat. 84: 61-71.